Highlights CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Market Closed - Hong Kong S.E. Other stock markets 01:38:07 18/06/2024 pm IST			5-day change	1st Jan Change
6.6 ^HKD	-1.05%		-4.35%	-9.09%

12/06	CSPC Pharmaceutical Buys Back Further Shares	MT
11/06	CSPC Pharmaceutical Repurchases 7 Million Shares	MT

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

CSPC Pharmaceutical Buys Back Further Shares	12/06	MT
CSPC Pharmaceutical Repurchases 7 Million Shares	11/06	MT
CSPC Pharmaceutical Trustee Repurchases Further Shares Under Award Scheme	07/06	MT
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic	06/06	RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China	06/06	RE
Corbus Pharmaceuticals Reaches 2-Year High After Drug Results	03/06	DJ
CSPC Pharmaceutical’s Trustee Buys Back Further Shares	03/06	MT
CSPC Pharmaceutical Group Limited Receives Approval for Olaparib Tablets by the National Medical Products Administration of the People's Republic of China	03/06	CI
Final dividend	31/05	FA
CSPC Pharmaceutical Repurchases 3 Million Shares	30/05	MT
CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023	28/05	CI
CSPC Pharmaceutical Group's Q1 Profit Rises 12%	27/05	MT
CSPC Pharmaceutical Group Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	27/05	CI
CSPC Pharma Gets Clearance for China Clinical Trial of Drug for Metabolism-Related Diseases	17/05	MT
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug Obtains Approval from National Medical Products Administration of the People's Republic of China	17/05	CI
CSPC Pharma's Flu Medication Gets Registration Approval in China	14/05	MT
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs	14/05	CI
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023	26/04	CI
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor Obtains Clinical Trial Approval in the U.S	26/04	CI
CSPC Pharmaceutical's EBT Buys 8.5 Million Shares	24/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights CSPC Pharmaceutical Group Ltd.

Equities

1093

HK1093012172

Highlights

Filters